Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease

Molecular Therapy

Volumn 8, Issue 1, 2003, Pages 29-41

  Rettig, Michael P ^a   Ritchey, Julie K ^a   Meyerrose, Todd E ^a   Haug, Jeffrey S ^a   DiPersio, John F ^a  

^a USA   (United States)

Author keywords

CD34 antigen; Chimeric proteins; Gene therapy; Immunomagnetic separation; T lymphocytes; Thymidine kinase

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CHIMERIC PROTEIN; GANCICLOVIR; MONOCLONAL ANTIBODY; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CELL SELECTION; CONTROLLED STUDY; GENE CONSTRUCT; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; SUICIDE GENE THERAPY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA; MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; MURINE LEUKEMIA VIRUS; ONCOVIRINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0042199069     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00142-4     Document Type: Article

References (55)

1. Luznik, L., and Fuchs, E. J. (2002). Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 9: 123-137.
2. Ferrara, J. L. M., Deeg, H. J., and Burakoff, S. J. (1997). Graft-vs.-Host Disease. 2nd rev. ed. Dekker, New York.
3. Tiberghien, P. (2001). Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J. Intern. Med. 249: 369-377.
4. Springer, C. J., and Niculescu-Duvaz, I. (2000). Prodrug-activating systems in suicide gene therapy. J. Clin. Invest. 105: 1161-1167.
5. Faulds, D., and Heel, R. C. (1990). Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39: 597-638.
6. Bonini, C., et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724.
7. Tiberghien, P., et al. (2001). Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97: 63-72.
8. Garin, M. I., et al. (2001). Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97: 122-129.
9. Verzeletti, S., et al. (1998). Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum. Gene Ther. 9: 2243-2251.
10. Link, C. J. Jr, et al. (1998). Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. Hum. Gene Ther. 9: 115-134.
11. Sauce D., et al. (2002). Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 99: 1165-1173.
12. Riddell, S. R., et al. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2: 216-23.
13. Di lanni, M., et al. (2000). T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection. Cancer Gene Ther. 7: 920-926.
14. Li, Z., et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
15. Emerman, M., and Temin, H. M. (1986). Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol. Cell. Biol. 6: 792-800.
16. Lupton, S. D., Brunton, L. L., Kalberg, V. A., and Overell, R. W. (1991). Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell. Biol. 11: 3374-3378.
17. Paquin, A., Jaalouk, D. E., and Galipeau, J. (2001). Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum. Gene Ther. 12: 13-23.
18. Thomis, D. C., et al. (2001). A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97: 1249-1257.
19. Fehse, B., et al. (2000). CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol. Ther. 1: 448-456, doi:10.1006/mthe.2000.0068.
20. Black, M. E., Newcomb, T. G., Wilson, H. M., and Loeb, L. A. (1996). Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA 93: 3525-3529.
21. Black, M. E., Kokoris, M. S., and Sabo, P. (2001). Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 61: 3022-3026.
22. Chalmers, D., et al. (2001). Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol. Ther. 4: 146-148 doi:10.1006/mthe.2001.0433.
23. Miller, D. G., Adam, M. A., and Miller, A. D. (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10: 4239-4242.
24. Gallardo, H. F., Tan, C., Ory, D., and Sadelain, M. (1997). Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90: 952-957.
25. Ferrand, C., et al. (2000). Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum. Gene Ther. 11: 1151-1164.
26. Marini, F. C. 3rd, and Kornblau, S. M. (1999). Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition. Bone Marrow Transplant. 23: 907-915.
27. Movassagh, M., et al. (2000). Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Hum. Gene Ther. 11: 1189-1200.
28. van den Beemd, R., et al. (2000). Flow cytometric analysis of the Vbeta repertoire in healthy controls. Cytometry 40: 336-345.
29. King, W., Patel, M. D., Lobel, L. I., Goff, S. P., and Nguyen-Huu, M. C. (1985). Insertional mutagenesis of embryonal carcinoma cells by retroviruses. Science 228: 554-558.
30. Stocking, C., et al. (1993). Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid cell line. Growth Factors 8: 197-209.
31. Laurendeau, I., et al. (1999). Taqman PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency. Clin. Chem. 45: 982-986.
32. Agarwal, M., et al. (1998). Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J. Virol. 72: 3720-3728.
33. Pollok, K. E., van der Loo, J. C., Cooper, R. J., Kennedy, L., and Williams, D. A. (1999). Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. Hum. Gene Ther. 10: 2221-2236.
34. Quinn, E. R., Lum, L. G., and Trevor, K. T. (1998). T cell activation modulates retrovirus-mediated gene expression. Hum. Gene Ther. 9: 1457-1467.
35. Lanza, F., Healy, L., and Sutherland, D. R. (2001). Structural and functional features of the CD34 antigen: an update. J. Biol. Regul. Homeostasis Agents 15: 1-13.
36. Fehse, B., Li, Z., Schade, U. M., Uhde, A., and Zander, A. R. (1998). Impact of a new generation of gene transfer markers on gene therapy. Gene Ther. 5: 429-430.
37. Healy, L., et al. (1995). The stem cell antigen CD34 functions as a regulator of hemopoietic cell adhesion. Proc. Natl. Acad. Sci. USA 92: 12240-12244.
38. Qasim, W., et al. (2002). T cell transduction and suicide with an enhanced mutant thymidine kinase. Gene Ther. 9: 824-827.
39. Pantuck, A. J., et al. (2002). Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum. Gene Ther. 13: 777-789.
40. Hamaguchi, I., et al. (2000). Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J. Virol. 74: 10778-10784.
41. Arai, T., Takada, M., Ui, M., and Iba, H. (1999). Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts. Virology 260: 109-115.
42. Pollok, K. E., et al. (1998). High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J. Virol. 72: 4882-4892.
43. Hacein-Bey-Abina, S., et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348: 255-256.
44. Baum, C., et al. (2003). Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101: 2099-2114.
45. Drobyski, W. R., Majewski, D., Ozker, K., and Hanson, G. (1998). Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. J. Immunol. 161: 2610-2619.
46. Tan, R., et al. (1999). Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 93: 1506-1510.
47. Weijtens, M., van Spronsen, A., Hagenbeek, A., Braakman, E., and Martens, A. (2002). Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats. Hum. Gene Ther. 13: 187-198.
48. + T cells in the absence of exogenous feeder cells. J. Immunol. 159: 5921-5930.
49. Shibuya, T. Y., et al. (2000). Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 126: 473-479.
50. Hammer, M. H., et al. (2000). Potential of allospecific gene-engineered T cells in transplantation gene therapy: specific T cell activation determines transgene expression in vitro and in vivo. Hum. Gene Ther. 11: 1303-1311.
51. Ory, D. S., Neugeboren, B. A., and Mulligan, R. C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93: 11400-11406.
52. Mansour, S. L., Thomas, K. R., and Capecchi, M. R. (1988). Disruption of the protooncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 336: 348-352.
53. Markowitz, D., Goff, S., and Bank, A. (1988). A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62: 1120-1124.
54. Persons, D. A., et al. (1999). Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood 93: 488-499.
55. Nolta, J. A., Dao, M. A., Wells, S., Smogorzewska, E. M., and Kohn, D. B. (1996). Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc. Natl. Acad. Sci. USA 93: 2414-2419.